At the AHA Sessions in Chicago, Illinois, a November 8 Poster on Evategrel: Chinese and U.S. Participants Showed Comparable Pharmacokinetics and Pharmacodynamics, and Food Slowed Absorption but Not Total Exposure
Results from two clinical pharmacology studies of Evategrel (CG-0255), an investigational P2Y12 receptor antagonist, were presented as a poster (Su4001, November 8, 11:30 a.m.–12:30 p.m.) at the American Heart Association Scientific Sessions 2026 in Chicago, Illinois, according to a release from its developer, CureGene. One study compared the pharmacokinetics and pharmacodynamics of oral Evategrel in Chinese and U.S. healthy volunteers; the other examined how food affects exposure to the oral formulation and its antiplatelet effect. The sessions run November 6–9 at McCormick Place in Chicago.
Both studies used the same design, one run in the United States and one in China, the company said. Oral Evategrel was absorbed quickly and cleared quickly, and at matched dose levels, plasma concentrations and platelet inhibition traced the same course in the two populations, with inhibition rising with dose rather than differing by ethnicity.
On food, the company said Evategrel taken on an empty stomach was absorbed faster and peaked sooner, while after a meal the peak came later and lower — but total exposure and the degree of platelet inhibition came out about the same either way, because the active metabolite H4 binds covalently and irreversibly to the P2Y12 receptor, so what matters is how much H4 accumulates over time. Taken orally, Evategrel produces clear platelet inhibition within about 30 minutes, the company said; the intravenous form is intended for the acute phase of ischaemic stroke, for patients who cannot swallow — a group the company put at roughly 40% of stroke patients on arrival.
Evategrel is a thiol prodrug: a single carboxylesterase-mediated hydrolysis step releases H4, the same active metabolite that clopidogrel produces, with no CYP450 oxidation involved, so onset does not depend on CYP2C19, according to the company. The company stated that the drug has not been approved by any regulatory authority and that its safety and efficacy are still being studied; a registration trial is running in the United States, and registration trials in China are due to begin shortly.
Source: CureGene
Published by GSM · USA (original Chinese edition)
Photo: 图：芝加哥麦考密克会展中心。User:TonyTheTiger 摄，CC BY-SA 3.0，经 Wikimedia Commons。 / Photo: McCormick Place, Chicago. Photo by User:TonyTheTiger, CC BY-SA 3.0, via Wikimedia Commons.
Yoga-CaRe Heart Failure Trial in Chicago, Illinois: 3,492 Patients Gained 8.1 Quality-of-Life Points and 25.5 Metres on the Six-Minute Walk at Three Months, With No Significant Difference in Death, Hospitalization or Stroke at 21.0% Versus 22.8%2026-11-08
OPTIMAL-DIABETES Trial at AHA Scientific Sessions in Chicago, Illinois: Intensive Blood Pressure Target Below 120 Did Not Significantly Cut Cardiovascular Events in 9,476 Adults With Type 2 Diabetes, 6% Versus 6.7%2026-11-08